AEON Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
AEON Biopharma, Inc. (AEON), a Delaware corporation, filed this Current Report on Form 8-K on February 3, 2025. The Company is an emerging growth company with its Class A Common Stock listed on the NYSE American under the symbol "AEON".
Key Financial Metrics
The filing discloses specific financial data related to listing compliance standards:
- Stockholders' Equity: The Company reported a stockholders' deficit of $32.1 million as of September 30, 2024.
- Profitability: The Company reported losses in the two most recent fiscal years ended December 31, 2023.
- Revenue, Cash Flow, and Debt: The filing text does not provide clear values for revenue, operating cash flow, or specific debt obligations.
Material Changes and Compliance Status
On February 3, 2025, AEON received a written notice of non-compliance from the NYSE American. The Company failed to meet Section 1003(a)(i) of the NYSE American Company Guide, which requires stockholders' equity of at least $2.0 million for companies reporting losses in two of their three most recent fiscal years. Due to the $32.1 million deficit and recent losses, the Company is currently below the Minimum Requirement.
Outlook, Risks, and Management Commentary
Compliance Plan and Timeline:
- The notice has no immediate effect on the listing status.
- The Company has been granted an 18-month compliance period to regain compliance.
- Plan Submission Deadline: March 5, 2025.
- Compliance Target Date: August 3, 2026.
Risks and Contingencies:
- If the Company fails to submit a plan, the plan is rejected, or the Company fails to meet the Minimum Requirement by August 3, 2026, the NYSE American will initiate delisting proceedings.
- Management stated there can be no assurance that the Company will be able to regain compliance.
- The Company intends to consider available options to resolve the non-compliance.
Investor Verification Checklist
- Verify the specific details of the compliance plan to be submitted by March 5, 2025.
- Monitor the Company's stockholders' equity position in upcoming quarterly reports to assess progress toward the $2.0 million threshold.
- Review the press release filed as Exhibit 99.1 for additional management commentary on capital raising or operational strategies.
- Confirm whether the Company has elected to use the extended transition period for new accounting standards as an emerging growth company.